DDX41 and AL amyloidosis: DDX41 mutations have been described in approximately 1–3% of MDS/AML patients and are also described to a lesser extent in multiple myeloma, lymphoma, chronic myelomonocytic leukemia (CMML), and myeloproliferative neoplasms (MPNs).